INmune Bio closed enrollment for its Phase 2 trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial is focused on patients with Early AD and biomarkers of elevated neuroinflammation. Enrollment of new patients into the trial was concluded after the Company determined that there are sufficient patients currently in screening to meet the trial’s target of 201 patients. All patients currently in the screening process will remain eligible to participate in AD02, which will likely result in modest over-enrollment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio initiated with an Outperform at Raymond James
- INmune announces initial results from Phase I/II trial of INKmune with mCRPC
- INmune Bio announces results of additional interim analysis of Phase 2 trial
- INmune Bio initiated with an Outperform at Scotiabank on Alzheimer’s potential
- Scotiabank starts INmune with Outperform on Alzheimer’s potential